Some rules everyone should follow,20% of portfolio limit in any individual stock, sell half on a doubling of cost basis. Just a lot safer that way. I know that doesn't help the current situation or answer any questions.
As far as where we are, we have a pending drug approval in the EU while not guaranteed the results are good enough to ask for early approval, pet construct has conditional approval and looks very promising for further research but we need partner to pay, neo is still unknown but the concept looks very promising and we will see the pre-clinical data shortly, we have several collaborations unfortunately not paying partners yet and we will see the early data from psa collaboration with Merck shortly, Sellas collaboration is paid for but a long way from possible drug approval, and we have other valuable pipeline constructs.
I really didn't see the price getting this low. Heavy shorting did a lot of damage and the company unwittingly cooperated with that with high burn rate, no significant deals for long period, confusion at the top with firing of DO, which resulted in an offering at $2. Given the company performance I peg fair value around $350 million market cap could be much more with the right data and deals but we haven't seen the most recent data yet and they still don't have deals to move the pipeline forward. Any significant deals and the value could increase significantly which is why we wait. For myself I am not selling any shares here and am still accumulating, doesn't mean I am recommending you buy any more sounds like you are over weight here already. As far as dream or nightmare nobody knows for sure but we will know by beginning of 2019.
Market Data 
Markets 
AI
